Results 41 to 50 of about 6,337 (198)

Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022

Therapies, 2023
Nirmatrelvir/ritonavir (Paxlovid®) is currently one of the few therapeutic options for coronavirus disease 2019 (COVID-19) curative treatment in non-oxygen-requiring adult patients at-high risk of progressing to severe disease. This recently approved boosted antiviral therapy presents a significant risk of drug-drug interactions (DDI).
Bihan, Kevin, Lipszyc, Lorène, Lemaitre, Florian, Dautriche, Anne, Fedrizzi, S, Atzenhoffer, Marina, Vitores, Aurélie, Page, Annabelle, Lebrun-Vignes, Bénédicte   +8 more
openaire   +4 more sources

REBOUND COVID-19 AFTER PAXLOVID IN 2 RELATED FAMILY MEMBERS

International Journal of Infectious Diseases, 2023
Intro: On May 24, 2022, the CDC issued a healthcare advisory after reports of COVID-19 symptoms returning (COVID-19 rebound) in certain patients two to eight days after treatment with Paxlovid (Ritonavir-Boosted Nirmatrevir). We describe two patients who
P. Periyasamy, T. Li Fen, N. Kori, U.A. Zainulabid   +3 more
doaj   +1 more source

Severe COVID-19 caused by persistent SARS-CoV-2 infection successfully treated with dual direct acting antivirals [PDF]

, 2022
We report the use of combination therapy with remdesivir and nirmatrelvir/ritonavir (Paxlovid) in successfully treating severe, chronic COVID-19 caused by persistent SARS-CoV-2 infection over 4 months.
Snell, Luke Blagdon, Bakrania, Prijay, Williams, Tom G.S., Tam, Jerry, Da Silva Fontoura, Dayana, Shaw, Emily, Daunt, Anna, Edgeworth, Jonathan, Hemsley, Carolyn J., Fields, Paul, Agarwal, Sangita, Lams, Boris, Cahill, Helen, Milligan, Iain, Botgros, Alina, Nebbia, Gaia, Douthwaite, Sam, Aarons, Emma J.   +17 more
core  

Familial Hypercholesterolemia Patients with COVID-19-Effective Cholesterol-Lowering Therapy is Urgent both during and after Infection [PDF]

, 2022
Heterozygous familial hypercholesterolemia (HeFH) patients are the prime example of subjects who are at high risk for both acute myocardial infarction (AMI) and ischemic stroke during, and post, SARS-CoV-2 infection.
Kovanen, Petri T., Raal, Frederick, Vuorio, Alpo   +2 more
core   +1 more source

The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir. [PDF]

, 2023
The SARS-CoV-2 main protease (3CLpro) has an indispensable role in the viral life cycle and is a therapeutic target for the treatment of COVID-19. The potential of 3CLpro-inhibitors to select for drug-resistant variants needs to be established. Therefore,
Bardiot, Dorothée, Beigelman, Leonid, Blatt, Lawrence M, Boland, Sandro, Chaltin, Patrick, De Jonghe, Steven, De Vita, Chloe, Deval, Jerome, Donckers, Kim, Ebert, Nadine, Jekle, Andreas, Jochmans, Dirk, Liu, Cheng, Maes, Piet, Marchand, Arnaud, Neyts, Johan, Raboisson, Pierre, Stevens, Sarah K, Stoycheva, Antitsa, Symons, Julian A, Thiel, Volker, Trüeb, Bettina, Vandyck, Koen, Vangeel, Laura, Vanmechelen, Bert   +24 more
core   +2 more sources

A case of the application of Paxlovid for a patient infected by the SARS-CoV-2 Omicron variant [PDF]

, 2023
Coronavirus disease 2019 (COVID-19) is a new acute respiratory infectious disease with high infectivity. To date, > 500 million cases of COVID-19 have been confirmed worldwide (World Health Organization).
Lu Zhang, Mei Wang, Xianwei Ye
core   +1 more source

SARS-CoV-2 Proteases: Role and Potential as Drug Target [PDF]

, 2023
The coronavirus disease of 2019 (COVID-19) has become a long global pandemic caused by a transmitted and pathogenic virus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Sudiro, Tjahjani Mirawati, Swestikaputri, Chrecentia Hanna   +1 more
core   +2 more sources

Paxlovid™ reduces the incidence of pneumonia, hospitalization, and death in a cohort of COVID-19 patients from northeast Mexico

Journal of Infection and Public Health
Background: Information on Paxlovid™ effectiveness must be monitored and updated in real world scenarios. Our research question was what is the effectiveness of Paxlovid™ in adult patients with COVID-19?
María Elena Camacho Moll, Ana Maria Salinas Martínez, Minna Wu, Gloria Navarrete Floriano, Juan Carlos Romo Salazar, Jorge Eleazar Cruz Luna, Mario Bermúdez de León   +6 more
doaj   +1 more source

Safety and Efficacy of Paxlovid Against Omicron Variants of Coronavirus Disease 2019 in Elderly Patients

Infectious Diseases and Therapy, 2023
Introduction Elderly patients are the most affected and vulnerable to COVID-19 and effective therapeutic interventions are urgently required. We clarified the safety and efficacy of Paxlovid in the treatment of elderly patients with coronavirus disease ...
Chengzhao Weng, Rongcheng Xie, Guanjie Han, Ya Yuan, Shiqin Li, Chao Wang, Xiaofeng Wang, Wei Jiang, Libo Jiang   +8 more
doaj   +1 more source

RECOVER Query: Paxlovid

, 2022
The overall goals of this query are to 1) characterize the growth in patients receiving Paxlovid over time and 2) examine Paxlovid use by patient characteristics, including by acute SARS CoV-2 infection profile and healthcare utilization. Patients with a COVID index date or a visit date between 12/1/2021 (7 days before EUA) and 5/30/2022 are included ...
openaire   +1 more source